Hsp22 ameliorates lipopolysaccharide-induced myocardial injury by inhibiting inflammation, oxidative stress, and apoptosis. 2021

Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
Department of Cardiovascular Medicine, Second Affiliated Hospital of Nanchang University, Nanchang, China.

Sepsis-induced myocardial dysfunction (SIMD) is ubiquitous in septic shock patients and is associated with high morbidity and mortality rates. Heat shock protein 22 (Hsp22), which belongs to the small HSP family of proteins, is involved in several biological functions. However, the function of Hsp22 in lipopolysaccharide (LPS)-induced myocardial injury is not yet established. This study was aimed at investigating the underlying mechanistic aspects of Hsp22 in myocardial injury induced by LPS. In this study, following the random assignment of male C57BL/6 mice into control, LPS-treated, and LPS + Hsp22 treated groups, relevant echocardiograms and staining were performed to scrutinize the cardiac pathology. Plausible mechanisms were proposed based on the findings of the enzyme-linked immunosorbent assay and Western blotting assay. A protective role of Hsp22 against LPS-induced myocardial injury emerged, as evidenced from decreased levels of creatinine kinase-MB (CK-MB), lactate dehydrogenase (LDH), and enhanced cardiac function. The post-LPS administration-caused spike in inflammatory cytokines (IL-1β, IL-6, TNF-α and NLRP3) was attenuated by the Hsp22 pre-treatment. In addition, superoxide dismutase (SOD) activity and B-cell lymphoma-2 (Bcl2) levels were augmented by Hsp22 treatment resulting in lowering of LPS-induced oxidative stress and cardiomyocyte apoptosis. In summary, the suppression of LPS-induced myocardial injury by Hsp22 overexpression via targeting of inflammation, oxidative stress, and apoptosis in cardiomyocytes paves the way for this protein to be employed in the therapy of SIMD.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009202 Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). Myocardial Disease,Myocardial Diseases,Myocardial Diseases, Primary,Myocardial Diseases, Secondary,Myocardiopathies,Primary Myocardial Disease,Cardiomyopathies, Primary,Cardiomyopathies, Secondary,Primary Myocardial Diseases,Secondary Myocardial Diseases,Cardiomyopathy,Cardiomyopathy, Primary,Cardiomyopathy, Secondary,Disease, Myocardial,Disease, Primary Myocardial,Disease, Secondary Myocardial,Diseases, Myocardial,Diseases, Primary Myocardial,Diseases, Secondary Myocardial,Myocardial Disease, Primary,Myocardial Disease, Secondary,Myocardiopathy,Primary Cardiomyopathies,Primary Cardiomyopathy,Secondary Cardiomyopathies,Secondary Cardiomyopathy,Secondary Myocardial Disease
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D006360 Heat-Shock Proteins Proteins which are synthesized in eukaryotic organisms and bacteria in response to hyperthermia and other environmental stresses. They increase thermal tolerance and perform functions essential to cell survival under these conditions. Stress Protein,Stress Proteins,Heat-Shock Protein,Heat Shock Protein,Heat Shock Proteins,Protein, Stress
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D017202 Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION). Heart Disease, Ischemic,Ischemia, Myocardial,Ischemic Heart Disease,Disease, Ischemic Heart,Diseases, Ischemic Heart,Heart Diseases, Ischemic,Ischemias, Myocardial,Ischemic Heart Diseases,Myocardial Ischemias

Related Publications

Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
August 2023, Current issues in molecular biology,
Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
October 2020, European journal of pharmacology,
Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
December 2019, Inflammation,
Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
March 2022, Saudi journal of biological sciences,
Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
January 2022, Frontiers in cell and developmental biology,
Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
September 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
November 2019, Medical science monitor : international medical journal of experimental and clinical research,
Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
December 2021, Bioengineered,
Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
August 2021, Journal of biological regulators and homeostatic agents,
Yun Yu, and Long-Long Hu, and Liang Liu, and Ling-Ling Yu, and Jun-Pei Li, and Jing-An Rao, and Ling-Juan Zhu, and Hui-Hui Bao, and Xiao-Shu Cheng
June 2014, Free radical biology & medicine,
Copied contents to your clipboard!